Pemetrexed Induced Thymidylate Synthase Inhibition in Non-Small Cell Lung Cancer Patients: A Pilot Study with 3′-Deoxy-3′-[18F]fluorothymidine Positron Emission Tomography

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Frings, Virginie ^a   van der Veldt, Astrid A M ^a   Boellaard, Ronald ^a   Herder, Gerarda J M ^b   Giovannetti, Elisa ^a   Honeywell, Richard ^a   Peters, Godefridus J ^a   Thunnissen, Erik ^a   Hoekstra, Otto S ^a   Smit, Egbert F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; DEOXYURIDINE; PEMETREXED; THYMIDYLATE SYNTHASE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; ANTINEOPLASTIC ANTIMETABOLITE; GLUTAMIC ACID DERIVATIVE; GUANINE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MTHFR PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFECT; DRUG RESPONSE; DRUG UPTAKE; ENZYME INHIBITION; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; OVERALL SURVIVAL; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD; DIAGNOSTIC USE; GENETIC POLYMORPHISM; GENETICS; LUNG TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; PATHOLOGY; PROGNOSIS; SCINTISCANNING; TIME; TISSUE DISTRIBUTION;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYURIDINE; DIDEOXYNUCLEOSIDES; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; NEOPLASM METASTASIS; OUTCOME ASSESSMENT (HEALTH CARE); POLYMORPHISM, GENETIC; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; THYMIDYLATE SYNTHASE; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 84878137126     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063705     Document Type: Article

References (36)

1. Goldstraw P, Ball D, Jett JR, Le CT, Lim E, et al. (2011) Non-small-cell lung cancer. Lancet 378: 1727-1740.
2. Janku F, Garrido-Laguna I, Petruzelka LB, Stewart DJ, Kurzrock R, (2011) Novel therapeutic targets in non-small cell lung cancer. J Thorac Oncol 6: 1601-1612.
3. Galvani E, Peters GJ, Giovannetti E, (2011) Thymidylate synthase inhibitors for non-small cell lung cancer. Expert Opin Investig Drugs 20: 1343-1356.
4. Joerger M, Omlin A, Cerny T, Fruh M, (2010) The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. Curr Drug Targets 11: 37-47.
5. Rollins KD, Lindley C, (2005) Pemetrexed: a multitargeted antifolate. Clin Ther 27: 1343-1382.
6. Takezawa K, Okamoto I, Okamoto W, Takeda M, Sakai K, et al. (2011) Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. Br J Cancer 104: 1594-1601.
7. Clarke SJ, Abratt R, Goedhals L, Boyer MJ, Millward MJ, et al. (2002) Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann Oncol 13: 737-741.
8. Rusthoven JJ, Eisenhauer E, Butts C, Gregg R, Dancey J, et al. (1999) Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17: 1194.
9. Perumal M, Pillai RG, Barthel H, Leyton J, Latigo JR, et al. (2006) Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography. Cancer Res 66: 8558-8564.
10. Wells P, Aboagye E, Gunn RN, Osman S, Boddy AV, et al. (2003) 2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337. J Natl Cancer Inst 95: 675-682.
11. Soloviev D, Lewis D, Honess D, Aboagye E, (2012) [(18)F]FLT: an imaging biomarker of tumour proliferation for assessment of tumour response to treatment. Eur J Cancer 48: 416-424.
12. Peters GJ, Honeywell RJ, Leon LG, van Groeningen J, Jansen G, et al. (2009) Role of Pharmacodynamic, Pharmacogenetic and Pharmacogenomic Biomarkers of Cancer Chemotherapy with Antifolates. Pteridines 20: 115-127.
13. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, et al. (2007) The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2: 706-714.
14. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, et al. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655.
15. Brix G, Zaers J, Adam LE, Bellemann ME, Ostertag H, et al. (1997) Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J Nucl Med 38: 1614-1623.
16. Patlak CS, Blasberg RG, Fenstermacher JD, (1983) Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 3: 1-7.
17. Bijnsdorp IV, Schwendener RA, Schott H, Fichtner I, Smid K, et al. (2011) Cellular pharmacology of multi- and duplex drugs consisting of ethynylcytidine and 5-fluoro-2′-deoxyuridine. Invest New Drugs 29: 248-257.
18. Honeywell R, Laan AC, Van Groeningen CJ, Strocchi E, Ruiter R, et al. (2007) The determination of gemcitabine and 2′-deoxycytidine in human plasma and tissue by APCI tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 847: 142-152.
19. Van TB, Loftus BM, Pinedo HM, Backus HH, Schoenmakers P, et al. (2000) Thymidylate synthase expression in patients with colorectal carcinoma using a polyclonal thymidylate synthase antibody in comparison to the TS 106 monoclonal antibody. J Histochem Cytochem 48: 755-760.
20. Takehara A, Kawakami K, Ohta N, Oyama K, Ota Y, et al. (2005) Prognostic significance of the polymorphisms in thymidylate synthase and methylenetetrahydrofolate reductase gene in lung cancer. Anticancer Res 25: 4455-4461.
21. Giovannetti E, Ugrasena DG, Supriyadi E, Vroling L, Azzarello A, et al. (2008) Methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate synthase promoter (TSER) polymorphisms in Indonesian children with and without leukemia. Leuk Res 32: 19-24.
22. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247.
23. de Langen AJ, Klabbers B, Lubberink M, Boellaard R, Spreeuwenberg MD, et al. (2009) Reproducibility of quantitative 18F-3′-deoxy-3′-fluorothymidine measurements using positron emission tomography. Eur J Nucl Med Mol Imaging 36: 389-395.
24. Frings V, de Langen AJ, Smit EF, van Velden FH, Hoekstra OS, et al. (2010) Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer. J Nucl Med 51: 1870-1877.
25. Akaike H, (1974) A new look at the statistical model identification. IEEE Trans Automatic Control 19: 716-726.
26. Vesselle H, Grierson J, Muzi M, Pugsley JM, Schmidt RA, et al. (2002) In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 8: 3315-3323.
27. Visvikis D, Francis D, Mulligan R, Costa DC, Croasdale I, et al. (2004) Comparison of methodologies for the in vivo assessment of 18FLT utilisation in colorectal cancer. Eur J Nucl Med Mol Imaging 31: 169-178.
28. Muzi M, Vesselle H, Grierson JR, Mankoff DA, Schmidt RA, et al. (2005) Kinetic analysis of 3′-deoxy-3′-fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med 46: 274-282.
29. Ford HE, Mitchell F, Cunningham D, Farrugia DC, Hill ME, et al. (2002) Patterns of elevation of plasma 2′-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331. Clin Cancer Res 8: 103-109.
30. Peters GJ, Backus HH, Freemantle S, Van TB, Codacci-Pisanelli G, et al. (2002) Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 1587: 194-205.
31. Pillai RG, Forster M, Perumal M, Mitchell F, Leyton J, et al. (2008) Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945. Cancer Res 68: 3827-3834.
32. van der Wilt CL, Marinelli A, Pinedo HM, Cloos J, Smid K, et al. (1995) The effect of different routes of administration of 5-fluorouracil on thymidylate synthase inhibition in the rat. Eur J Cancer 31A: 754-760.
33. van der Wilt CL, Van Groeningen CJ, Pinedo HM, Smid K, Hoekman K, et al. (1997) 5-fluorouracil/leucovorin-induced inhibition of thymidylate synthase in normal tissues of mouse and man. J Cancer Res Clin Oncol 123: 595-601.
34. Kenny LM, Contractor KB, Stebbing J, Al-Nahhas A, Palmieri C, et al. (2009) Altered tissue 3′-deoxy-3′-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography. Clin Cancer Res 15: 6649-6657.
35. Contractor KB, Kenny LM, Stebbing J, Rosso L, Ahmad R, et al. (2011) [18F]-3′Deoxy-3′-fluorothymidine positron emission tomography and breast cancer response to docetaxel. Clin Cancer Res 17: 7664-7672.
36. Hammad H, Sarkar M, Gupta N, Ardalan B, Subbarayan PR, (2012) The presence of three repeats in the 5′ UTR region of thymidylate synthase (TS) is associated with increased TS mRNA expression in cultured human cancer cell lines in vitro. Oncol Rep 27: 246-249.